COMMUNIQUÉS West-GlobeNewswire
-
MITHRA SIGNS EXCLUSIVE LICENSE AND SUPPLY AGREEMENT WITH FUJI PHARMA FOR DONESTA® IN JAPAN AND ASEAN
28/06/2017 - 07:30 -
MDxHealth Presents Three SelectMDx Studies at 5th Global Congress on Prostate Cancer
28/06/2017 - 07:00 -
MDxHealth présente trois études SelectMDx lors du 5e congrès mondial sur le cancer de la prostate
28/06/2017 - 07:00 -
Minerva Neurosciences, Inc. to Offer Common Shares
27/06/2017 - 22:10 -
La demande relative aux interventions de chirurgie esthétique dans le monde continue de s'envoler : les États Unis, le Brésil, le Japon, l'Italie et le Mexique classés comme les cinq principaux pays
27/06/2017 - 20:25 -
Nestlé outlines future value creation model including strategic growth priorities and supporting capital structure
27/06/2017 - 18:01 -
Mithra Pharmaceuticals: INFORMATION ON THE TOTAL NUMBER OF VOTING RIGHTS (DENOMINATOR)
27/06/2017 - 17:45 -
Nuvaira Announces Enrollment Completion in First Sham-Controlled Clinical Trial of Targeted Lung Denervation for COPD
27/06/2017 - 15:00 -
Nuvaira annonce l'achèvement de l'inscription pour le premier essai clinique à groupe témoin fictif contre la dénervation pulmonaire ciblée pour la MPOC
27/06/2017 - 15:00 -
Bavarian Nordic Announces Positive Data from Ongoing Phase 2 Study Investigating a Universal RSV Vaccine
27/06/2017 - 13:59 -
Arix Bioscience participates in $20 million fundraise for Mitoconix Bio
27/06/2017 - 13:00 -
Affimed Presents Preclinical Data on AFM24 and AFM26 at EACR-AACR-SIC 2017
27/06/2017 - 11:00 -
Demand for Cosmetic Surgery Procedures Around the World Continues to Skyrocket - USA, Brazil, Japan, Italy and Mexico Ranked in the Top Five Countries
27/06/2017 - 10:00 -
Nexstim Plc Files 510(k) Submission for its NBT® system for the Treatment of Depression with US FDA
27/06/2017 - 08:00 -
Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across Europe
27/06/2017 - 08:00 -
Sanofi and Regeneron Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union
27/06/2017 - 07:00 -
Sanofi et Regeneron annoncent l'approbation de Kevzara® (sarilumab) dans l'Union européenne pour le traitement de la polyarthrite rhumatoïde active, modérée à sévère, de l'adulte
27/06/2017 - 07:00 -
ABLYNX ACHIEVES SECOND MILESTONE IN IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO., INC., KENILWORTH, NEW JERSEY, USA
27/06/2017 - 07:00 -
Ossur Hf : Transactions in relation to share buyback program
26/06/2017 - 18:00
Pages